Cargando…
Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment
Glioblastoma (GBM) is the most common primary brain tumor, carrying a very poor prognosis, with median overall survival at about 12 to 15 months despite surgical resection, chemotherapy with temozolomide (TMZ), and radiation therapy. GBM recurs in the vast majority of patients, with recurrent tumors...
Autores principales: | Liu, Kristie, Tsung, Kathleen, Attenello, Frank J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759649/ https://www.ncbi.nlm.nih.gov/pubmed/33363039 http://dx.doi.org/10.3389/fonc.2020.608911 |
Ejemplares similares
-
GRP78: A cell's response to stress
por: Ibrahim, Ibrahim M., et al.
Publicado: (2019) -
GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells
por: Ibanez, Jorge, et al.
Publicado: (2023) -
Cell surface GRP78 as a biomarker and target for suppressing glioma cells
por: Kang, Bo Ram, et al.
Publicado: (2016) -
Extracellular Hsp90α Supports the ePKM2-GRP78-AKT Axis to Promote Tumor Metastasis
por: Zhang, Shaosen, et al.
Publicado: (2022) -
GRP78 in lung cancer
por: Xia, Shengkai, et al.
Publicado: (2021)